Merck & Co., Inc. (NYSE:MRK) Stock Price Target Raised at Guggenheim

Merck & Co., Inc. (NYSE:MRK) had its price objective increased by research analysts at Guggenheim from $170.00 to $171.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s price objective suggests a potential upside of 16.87% from the stock’s previous close.

Several other analysts have also weighed in on the company. Scotiabank upped their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the company a “sector outperform” rating in a report on Tuesday, September 29th. Citigroup upped their price objective on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the company a “neutral” rating in a research note on Monday, October 12th. HSBC raised their target price on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Jefferies Financial Group lifted their target price on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Finally, Weiss Ratings upgraded Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 25th. Seventeen equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $153.16.

Merck & Co., Inc. Stock Up 3.8%

MRK stock opened at $146.32 on Friday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The stock has a market capitalization of $360.99 billion, a PE ratio of 117.05, a price-to-earnings-growth ratio of 6.49 and a beta of 0.21. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92. The company has a fifty day moving average of $146.89 and a 200-day moving average of $126.49.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company had revenue of $18.09 billion for the quarter, compared to analysts’ expectations of $17.33 billion. During the same quarter in the previous year, the firm posted $2.58 EPS. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. As a group, analysts expect that Merck & Co., Inc. will post 2.64 EPS for the current year.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 20,784 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $130.43, for a total value of $2,710,857.12. Following the completion of the sale, the executive vice president directly owned 134,703 shares in the company, valued at $17,569,312.29. This represents a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 228,238 shares of company stock worth $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its stake in Merck & Co., Inc. by 0.5% in the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after purchasing an additional 1,073,507 shares during the period. State Street Corp increased its position in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after purchasing an additional 1,087,583 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Merck & Co., Inc. by 2.3% during the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock worth $11,083,033,000 after purchasing an additional 1,934,312 shares during the period. Bank of America Corp DE raised its stake in shares of Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after purchasing an additional 2,919,780 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Merck & Co., Inc. by 23.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock worth $1,858,938,000 after buying an additional 2,969,856 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported third-quarter adjusted earnings of $2.49 per share, well above the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, exceeding expectations of $17.33 billion. Merck third-quarter 2026 financial results
• Positive Sentiment: The company raised its 2026 adjusted profit outlook and projected full-year revenue of approximately $66.8 billion to $67.3 billion. A lower tax rate also helped support the improved earnings forecast. Merck boosts fiscal 2026 outlook
• Positive Sentiment: KEYTRUDA, including the newer QLEX formulation, delivered stronger-than-expected sales, while WINREVAIR continued to grow rapidly. These products are helping offset declines from older medicines and generic competition. Merck tops quarterly estimates
• Positive Sentiment: New cancer data provided additional pipeline support: KEYTRUDA reduced the risk of disease progression by 43% in a Phase 3 endometrial-cancer trial, while sacituzumab tirumotecan produced positive late-stage results and received FDA priority review. Merck endometrial cancer data and FDA review
• Neutral Sentiment: Management said new launches and WINREVAIR growth create momentum, but some reported revenue benefited from roughly $550 million in customer-purchase timing, implying underlying growth was more modest. Merck lifts outlook on lower tax rate
• Negative Sentiment: Investors remain concerned about generic headwinds in 2027 and the eventual KEYTRUDA patent cliff, which could pressure long-term revenue and earnings despite near-term operating strength. Merck earnings and Keytruda patent cliff
• Negative Sentiment: A law firm announced an investigation into potential securities-law violations related to prior company disclosures. The announcement is not an allegation finding, but it adds headline and litigation risk. Merck securities investigation

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.